Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioScience Health Innovations's revenue for the
three
months ended in Mar. 2026 was $0.75 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $5.21 Mil.
BioScience Health Innovations's Revenue per Share for the
three
months ended in Mar. 2026 was $0.07.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.47.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BioScience Health Innovations Revenue Related Terms
BioScience Health Innovations Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's Revenue distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations (BHIC) has a Revenue of $5.21 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on BioScience Health Innovations and its competitors.
Is BioScience Health Innovations' Revenue too high?
BioScience Health Innovations' current Revenue is $5.21 Mil. Overall, BioScience Health Innovations has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' Revenue compare to SHFH and PETS?
BioScience Health Innovations' Revenue of $5.21 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on BioScience Health Innovations and its competitors. BioScience Health Innovations's current Revenue is $5.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.04 — trading 97.5% below its estimated fair value. The current Revenue is $5.21 Mil. BioScience Health Innovations' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current Revenue is $5.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $4.04 is trading 97.5% below its estimated GF Value™ of $164.84.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
Revenue: $5.21 Mil
GF Value™: $164.84 vs. price of $4.04 (97.5% below fair value)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Business Description
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
49GF Score
Get the complete analysis for BHIC
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
